The call for Collaborate to Innovate round 2 is now open and will close on 21 March 2019
Advanced Therapies (gene and cell based treatments) is a fast growing area of research and innovation in life sciences, with the potential to provide a step-change in the treatment of many diseases.
Funded by the Research England Connecting Capabilities Fund as part of the London Advanced Therapies programme, this round of Collaborate to Innovate offers a focused and intensive end-to-end solution for SMEs working in advanced therapies with specific R&D needs. It helps define those needs, then matches them to expertise in Higher Education Institutes and delivers research collaborations with the aim of leading to innovative advanced therapies products.
Each of the participating SMEs in the scheme will receive support to help them tap into academic expertise and key capabilities from the university delivery partners up to a value of £100,00 – 150,000 which is paid for by the programme.
Collaborate to Innovate round 2 is managed centrally by MedCity and delivered through the following academic delivery partners:
- King’s College London
- University College London
- Imperial College London.
Target SMEs include advanced therapies biotech companies working in the area of gene or cell therapy products, gene engineering, regenerative medicine, supply chain, vector manufacturing, and specialist equipment companies and related technology.More Information and Application Details